SCHEMBL21652051

SCHEMBL21652051

CCN1CCC(C)(NC(=O)c2ccccn2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 1/20 0.46
KDR P35968 1/20 0.46
KDM4E B2RXH2 4/20 0.45
GAA P10253 2/20 0.45
KMT2A Q03164 2/20 0.45
RET P07949 1/20 0.45
ANO1 Q5XXA6 1/20 0.45
FPR2 P25090 1/20 0.45
GRM5 P41594 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
HSD17B10 Q99714 2/20 0.44
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
MITF O75030 1/20 0.43
PKM P14618 1/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
OPRD1 P41143 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069803 0.85 KDM4E (0.48) KDM4EGAAKMT2ARETANO1
SCHEMBL29836003 0.85 GRM5 (0.53) KDM4EGAAKMT2AANO1FPR2
SCHEMBL21651966 0.84 P2RX7 (0.41) KDM4ERETANO1NPC1RAB9A
SCHEMBL25504255 0.84 P2RX7 (0.48) KMT2ARETANO1OPRD1
SCHEMBL30043736 0.82 GRM5 (0.57) KDM4EGAAKMT2AANO1FPR2
SCHEMBL20626718 0.82 KDM4E (0.45) KDM4EGAAKMT2ARETANO1
SCHEMBL20147607 0.82 KDM4E (0.47) KDM4EGAAKMT2ARETANO1
SCHEMBL20205745 0.81 KMT2A (0.44) KDM4EGAAKMT2ARETANO1
SCHEMBL25504250 0.80 P2RX7 (0.51) KDM4ERETSMN1; SMN2OPRD1
SCHEMBL21651965 0.78 RET (0.45) KMT2ARETL3MBTL1SMN1; SMN2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2020-12-10 US disclosed
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA, INC. 2020-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383966-A9 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RAD52 4163/4885KDR 972/4885KDM4E 547/4885
US-20200030311-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 RAD52 4163/4885KDR 972/4885KDM4E 547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.